
The Federal Trade Commission (FTC) is strongly backing the argument that the economy is better off with competing generic drugs. In “Authorized Generics: An Interim Report,” FTC analysts report that when 2 generics are on the market immediately after a patent on a branded drug expires, wholesale prices of the drug are 6.5% lower on average than when only 1 generic is available; retail prices are 4.2% lower on average.

